Replies to post #124 on Precision BioSciences Inc (DTIL)

[jondoeuk]

It is ''personalised'' in a sense. ADAP will be responsible for developing clinical candidates using its iPSC platform, while Genentech responsible for the input of patient-specific neoantigen-reactive TCRs and subsequent clinical development and commercialisation.